05/31/2016 - 1:29pm

Technavio on Tuesday published its report on the global generic drugs market, which highlights 49 vendors expected to impact the market between 2016 and 2020. 

05/31/2016 - 1:16pm
The Economic Times is reporting that drugmaker Sun Pharma recently received a subpoena from the Department of Justice looking for information about its U.S. subsidiary’s practices in selling and marketing the company’s generics. The report noted that this is the latest move in a larger regulatory interest in generic drug prices in the last year. (Economic Times)
05/31/2016 - 12:50pm

The drug will be available in 50- and 200-mg dosage strengths. 

05/25/2016 - 2:20pm

 The drug had sales of about $60.3 million in the U.s. for the 12 months ended March 2016, according to IMS Health. 

05/25/2016 - 11:49am

CVS Health’s efforts to dispense opioid overdose reversal drug naloxone without a prescription has already come to 23 states and the company has announced plans to expand to seven more over the course of the summer.

05/24/2016 - 1:15pm

The drug is indicated for acute treatment of migraines and will be available in 2.5- and 5-mg dosage strengths. 

05/24/2016 - 9:43am

The New York Times reports that the number of opioid prescriptions in the United States is falling for the first time since OxyContin hit the market in 1996. (New York Times)

05/23/2016 - 11:16am
Mylan will have 180 days of marketing exclusivity for the product, which had U.S. sales of about $181.8 million in the 12 months ended March 31, according to IMS Health.
05/20/2016 - 3:12pm

The drug is indicated to treat high cholesterol and high triglycerides, and will be available in 48- and 145-mg dosage strength.